RT Journal Article
SR Electronic
T1 Ex vivo human leukemia blood model illustrates limitations of cancer-targeting PEGylated nanoparticles
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.29.24308091
DO 10.1101/2024.05.29.24308091
A1 Ju, Yi
A1 Li, Shiyao
A1 Qi Tan, Abigail Er
A1 Pilkington, Emily H.
A1 Brannon, Paul T.
A1 Plebanski, Magdalena
A1 Cui, Jiwei
A1 Caruso, Frank
A1 Thurecht, Kristofer J.
A1 Tam, Constantine
A1 Kent, Stephen J.
YR 2024
UL http://medrxiv.org/content/early/2024/05/31/2024.05.29.24308091.abstract
AB Antibody-directed targeting of chemotherapeutic nanomaterials to primary human cancers could improve efficacy and reduce off-target toxicities. We developed an ex vivo model to study the targeting of primary human Chronic Lymphocytic Leukemia (CLL) in whole blood samples from 15 subjects with CLL. Anti-CD20 targeted polyethylene glycol (PEG)-based nanoparticles had generally efficient targeting of CLL cells and low off-target phagocytosis by neutrophils and monocytes. There was however substantial patient-patient variability (up to 164-fold difference in CLL targeting), driven in part by variance in pre-existing anti-PEG antibodies which reduced targeting effects. This suggests patients with lower PEG antibody levels may benefit more from targeted therapies. This was further exemplified by antibody-functionalized doxorubicin-containing PEGylated liposomes, which had relatively poor targeting of CLL in blood and high off-target uptake (significantly correlated with anti-PEG IgG levels in blood) and killing of almost all monocytes within 24 hours. Personalized low-fouling and non-PEGylated particle systems are needed to realize the potential of targeting chemotherapies. Overall, our human ex vivo model of tumor targeting by antibody-directed nanoparticles delineates limitations and opportunities of tumor-targeting nanomedicines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by an Australian Research Council (ARC) Discovery Project (DP210103114 to FC, SJK, YJ), an ARC Discovery Early Career Researcher Award (DE230101542 to YJ), a Maxwell Eagle Endowment Award for Cancer Research (to YJ and SJK), an RMIT Vice-Chancellors Postdoctoral Fellowship (to YJ), an NHMRC program grant (GNT1149990 to SJK), and NHMRC Investigator grants (SJK, GNT2016732 to FC, KT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the University of Melbourne and Royal Melbourne Hospital Human Research Ethics Committee (# 2057981.1, 13/36, 22993-34586-3) and all associated procedures were carried out in accordance with the approved guidelines.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors